ArticleJournal of Cancer2019
Combination of PET and CXCR4-Targeted Peptide Molecule Agents for Noninvasive Tumor Monitoring.
Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A noval noninvasive targeted therapy for osteosarcoma: the combination of LIFU and ultrasound-magnetic-mediated SPIO/TP53/PLGA nanobubble.Frontiers in bioengineering and biotechnology · 2024Article
- In Vivo Targeting of CXCR4-New Horizons.Cancers · 2021Review
- Identification of Critical Genes and Signaling Pathways in Human Monocytes Following High-Intensity Exercise.Healthcare (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision medicine is emphasizing not only at individual but also at disease molecule level in modern medicine. Therefore, target-specific molecular agents are crucial for precise diagnosis and treatment. We developed a peptide agent that binds a critical chemokine receptor-CXCR4 and could be used to detect tumor status. Confocal images showed binding of the peptide agent to human osteosarcoma cells. Clinical gold-standard molecular imaging agent PET showed tumors had high glucose metabolism, CT showed that these xenograft tumors were calcified and displayed hypervascularity. Peptide imaging demonstrated that these tumors were CXCR4 positive. However, Western blot protein analysis revealed a discordance between the tumor and the CXCR4 targeted agent, suggesting that small changes in peptide sequences have profound effect on binding to their targets. We also demonstrated the molecular screening by modifying the peptide sequence and thereby altering the binding properties of the agent. In conclusion, this study demonstrates that small molecule peptide agents can be used as an additional diagnostic tool for precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.